Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn Sells 15,000 Shares

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total value of $630,600.00. Following the completion of the transaction, the vice president now owns 24,344 shares of the company’s stock, valued at approximately $1,023,421.76. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Victor Vaughn also recently made the following trade(s):

  • On Friday, January 12th, Victor Vaughn sold 5,750 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $45.03, for a total value of $258,922.50.
  • On Tuesday, January 2nd, Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00.

Supernus Pharmaceuticals Inc (NASDAQ SUPN) opened at $42.75 on Wednesday. The company has a market capitalization of $2,263.22, a PE ratio of 40.33 and a beta of 1.18. Supernus Pharmaceuticals Inc has a 1 year low of $23.10 and a 1 year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% compared to the same quarter last year. equities analysts expect that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of SUPN. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC grew its position in Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 1,462 shares during the last quarter. Advisor Group Inc. grew its position in Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 410 shares during the last quarter. Victory Capital Management Inc. grew its position in Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after acquiring an additional 517 shares during the last quarter. Finally, Flinton Capital Management LLC grew its position in Supernus Pharmaceuticals by 88.9% during the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after acquiring an additional 2,240 shares during the last quarter. Institutional investors and hedge funds own 98.22% of the company’s stock.

A number of analysts recently issued reports on the company. BidaskClub raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Piper Jaffray Companies reissued a “hold” rating and set a $41.00 price objective on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Wednesday, January 10th. Cantor Fitzgerald reissued a “buy” rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $49.90.

COPYRIGHT VIOLATION NOTICE: This article was reported by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/supernus-pharmaceuticals-inc-supn-vp-victor-vaughn-sells-15000-shares/1822012.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.